Rheumatology - Medtelligence

Episodes 1-5 of 5

Exploring Developments in IgAN and FSGS
Exploring Developments in IgAN and FSGS
CME/CE
Exploring Developments in IgAN and FSGS
0.25 credits
- Howard Trachtman, MD, FASN
  Peer
- Richard Lafayette, MD, FACP
  Peer
0.25 credits
Can We Do Better in IgAN?
Can We Do Better in IgAN?
CME/CE
Can We Do Better in IgAN?
0.25 credits
- Jonathan Barratt, PhD
  Peer
- Annette Bruchfeld, MD, PhD
  Peer
0.25 credits
Understanding IgAN & FSGS: Pathophysiology and Emerging Therapies
Understanding IgAN & FSGS: Pathophysiology and Emerging Therapies
CME/CE
Understanding IgAN & FSGS: Pathophysiology and Emerging Therapies
0.50 credits
- Jonathan Barratt, PhD
  Peer
- Donald E. Kohan, MD, PhD
  Peer
0.50 credits
Case-Based Management of AAV
Case-Based Management of AAV
CME/CE
Case-Based Management of AAV
0.25 credits
- David Jayne, MD
  Peer
- Annette Bruchfeld, MD, PhD
  Peer
0.25 credits
Pinpointing the Top Questions about Biosimilars in Rheumatology
Pinpointing the Top Questions about Biosimilars in Rheumatology
CME/CE
Pinpointing the Top Questions about Biosimilars in Rheumatology
- Leonard H. Calabrese, DO
  Peer
- John R. Tesser, MD
  Peer